William S. Richmond

Partner Healthcare & Life Sciences Regulatory

Washington, D.C. +1 202 389 3222

William S. Richmond

Overview

Will Richmond is a corporate healthcare partner in the Washington, D.C., office of Kirkland & Ellis LLP. Will provides legal counsel to private equity funds, venture capital, and public and private companies with a focus in a broad range of healthcare transactions and regulatory matters. Will’s experience includes providing transactional and regulatory compliance advice across a broad spectrum of industries including healthcare providers, management/dental support organizations, pharmacies, medical device companies, drug manufacturers, health insurance providers, pharmacy benefit managers, managed care organizations, contract development and manufacturing organizations, clinical trial operators, and non-profit healthcare providers and hospital systems.

Will regularly advises on all aspects of healthcare transactions including term sheet negotiations, transaction structure, diligence, regulatory filings, RWI processes and lender negotiations. He also advises companies on new and proposed laws and regulations, commercial contract negotiations, physician contracting, healthcare investigations, and regulatory audits and inspections. Will’s extensive subject matter experience includes healthcare fraud and abuse laws such as the Anti-Kickback Statute and the Stark Law, FDA compliance requirements, healthcare reimbursement, HIPAA, corporate compliance programs, the corporate practice of medicine, and transactions involving state and federal tax-exempt entities. Will also helps clients navigate the growing regulatory requirements imposed by state healthcare transaction laws and has He also advises clients on healthcare regulatory matters incident to restructurings, bankruptcies and liability management transactions.

Healthcare Providers

  • Brookfield in its $185 million strategic investment into Orthopedic Care Partners
  • Silver Oak backed-Integrated Oncology Network, a provider of oncology services, in its $1.115 billion sale to Cardinal Health (NYSE: CAH)
  • VSP Vision in its acquisition of Eyemart Express from FFL Partners and Leonard Green & Partners
  • Cressey & Company in the acquisition of HealthDrive, a provider of clinical services to patients residing in long-term care facilities, from Bain Capital Double Impact
  • TPG's The Rise Fund in its investment in Banyan Treatment Centers, a provider of substance use disorder and mental health services
  • Vertava Health of Mississippi, a provider of addiction treatment and mental health services, in its sale to Bradford Health Services
  • Percheron Capital-backed Animal Dermatology Group in its acquisition of Animal Dermatology and Allergy Specialists
  • Seattle Reproductive Medicine, a fertility center, in its sale to Pinnacle Fertility

Healthcare Technology

  • Bain Capital Tech Opportunities in its investment in the combination of Greenphire, a provider of clinical trial payments, financial management and patient support tools, and Suvoda, a clinical trial technology company
  • Trinity Hunt Partners in its investment in TNT Dental, a digital marketing agency
  • GTCR, alongside Avryo Health Services, in its investment in 7to7 Dental, a dental service organization
  • Trinity Hunt Partners in its investment in Coker, a healthcare advisory firm
  • GTCR-backed RevSpring, a provider of communication and payment solutions, in its sale to Frazier Healthcare Partners 
  • Olympus Partners in the sale of Soliant, a provider of workforce solutions in K-12 school districts and healthcare facilities, to The Vistria Group
  • Stone Point Capital-backed Tivity Health in its acquisition of Burnalong, a digital health, wellness and fitness platform
  • EW Healthcare Partners in its acquisition of Enercon Technologies, a provider of electronic product development and manufacturing services
  • Vesey Street Capital Partners in its sale of QualityMetric, a provider of tools and technology that measure health from the patient's point of view
  • Olympus Partners in its acquisition of EyeSouth Partners, an eye care management services organization, from Shore Capital Partners
  • Francisco Partners in its acquisition of the healthcare data and analytics assets from IBM (NYSE: IBM) that are currently part of the Watson Health business
  • Thoma Bravo in its $6.9 billion acquisition of SailPoint Technologies (NYSE: SAIL), enterprise identity security provider
  • Bain Capital Private Equity in its investment in CitiusTech, a provider of technology and consulting services to healthcare and life sciences companies

Life Sciences

  • BayPine in its acquisition of CenExel Clinical Research, a provider of a clinical trial site network
  • Olympus Partners in its acquisition of PAI Pharma
  • Owens & Minor (NYSE: OMI) in its pending $1.36 billion acquisition of Rotech Healthcare, a provider of home medical equipment
  • Avista Healthcare Partners in its acquisition of Trillium Health Care Products, a contract development and manufacturing organization of branded over-the-counter products, from New Water Capital
  • Trilantic North America in its investment in SOFIE Biosciences, a Positron Emission Tomography (PET) radiopharmacy and contract development and manufacturing organization (CDMO)
  • Silver Oak backed-Integrated Oncology Network, a provider of oncology services, in its pending $1.115 billion sale to Cardinal Health (NYSE: CAH)
  • EQT-led consortium in the £4.5 billion acquisition of Dechra Pharmaceuticals (LSE: DPH), a provider of specialist veterinary pharmaceuticals and related products
  • Nordic Capital in its acquisition of IntegriChain, a platform for pharma commercialization and market access, from Accel-KKR
  • Bristol Myers Squibb (NYSE: BMY) in its $5.8 billion acquisition of Mirati Therapeutics (NASDAQ: MRTX), a commercial stage research and development biotechnology company
  • Owens & Minor (NYSE: OMI) in its $1.6 billion acquisition of Apria (NASDAQ: APR), a provider of integrated home healthcare equipment and related services
  • EQT-backed Recipharm in its acquisition of Arranta Bio, an advanced therapy medicinal products (ATMPs) contract development and manufacturing organization (CDMO), from Ampersand Capital Partners
  • EQT-backed Recipharm in its acquisition of Vibalogics, a virotherapy contract development and manufacturing organization (CDMO), from Ampersand Capital Partners
  • The Jordan Company in its investment in WEP Clinical, a specialist pharma services company that works with drug developers to help patients and physicians gain early access to medicines

Restructuring

  • Invitae Corporation and certain of its affiliates in their prearranged Chapter 11 cases in the U.S. Bankruptcy Court for the District of New Jersey. Invitae is headquartered in San Francisco, California and is a leader in the genetic testing field. Prior to commencing Chapter 11, Invitae secured support to implement a go-forward sale process by signing a transaction support agreement with a significant majority of its secured noteholders
  • Eyecare Service Partners in its $563 million recapitalization

Nelson Mullins Riley & Scarborough 

Ernst & Young

Will provides pro bono legal counsel to individuals seeking Special Immigrant Juvenile classification. 

More

Thought Leadership

Publications

Co-Author, “The Evolving Landscape of State Health Care Transaction Review Laws,” The American Health Law Association, Top Ten Issues in Health Law 2025

Credentials

Admissions & Qualifications

  • District of Columbia
  • New York

Education

  • American University School of International ServiceM.A., International Affairs2020
  • New York University School of LawLL.M., Taxation2018
  • American University Washington College of LawJ.D.cum laude2017
    Editor-in-Chief, National Security Law Brief
  • Clemson UniversityB.A., Political Science2014